Francesco Cuccia1, Gianluca Mortellaro2, Giovanna Trapani3, Vito Valenti1, Lucia Ognibene4, Giorgia De Gregorio1, Emanuele Quartuccio1, Nicoletta Luca1, Antonella Tripoli1, Vincenzo Serretta5, Antonio Lo Casto6, Giuseppe Ferrera2. 1. Department of Radiation Oncology, ARNAS Civico Hospital, Radiation Oncology School, University of Palermo, Palermo, Italy. 2. Department of Radiation Oncology, ARNAS Civico Hospital, Palermo, Italy. 3. Department of Radiation Oncology, ARNAS Civico Hospital, Radiation Oncology School, University of Palermo, Palermo, Italy. giovannatrapani91@gmail.com. 4. Department of Radiation Oncology, San Gaetano Radiotherapy and Nuclear Medicine Center, Bagheria, Palermo, Italy. 5. Department of Surgical Oncological and Oral Sciences, Section of Urology, University of Palermo, Palermo, Italy. 6. Radiation Oncology School, Section of Radiology - Di.Bi.Med, University of Palermo, Palermo, Italy.
Abstract
AIMS: To assess toxicity and clinical outcomes of moderately hypofractionated helical tomotherapy (HT) for the curative treatment of localized prostate cancer (PC). METHODS: From December 2012 to May 2018, 170 patients were treated with definitive intent for PC. Thirty-four percent were low risk, 30% intermediate risk (IR) and 36% high risk (HR). All patients received 70 Gy in 28 fractions to the prostate; 61.6 Gy were delivered to the seminal vesicles for IR; pelvic lymph nodes irradiation for a total dose of 50.4 Gy was added in the HR subgroup. Toxicity was assessed using CTCAE V4.0, and biochemical failure was defined following Phoenix criteria. Time-to-event data were analyzed using the Kaplan-Meier method and log-rank test. RESULTS: The median follow-up was 36 months (range 12-78); acute toxicity was as follows: G1 and G2 in 27.6% and 19.4% for GI; 53% and 24% for GU. No G ≥ 3 event was observed. For late toxicity, G ≥ 3 GI and GU rates were, respectively, 3% and 2.4% at 3 years and 3% and 4.8% at 4 years; no G4 occurred. A statistical correlation between acute or late G3 incidence and clinical or dosimetric parameters was not found. At the time of analysis, 2- and 3-year biochemical relapse-free survival rates were 90% and 87.5% and 2- and 3-year overall survival rates were 96.4% and 90%, respectively. The log-rank test revealed no difference between the risk groups in terms of biochemical control (p = 0.16). CONCLUSIONS: Moderately hypofractionated RT with HT for localized prostate cancer reported excellent outcomes with mild acute and late toxicity incidence, with promising biochemical control rates.
AIMS: To assess toxicity and clinical outcomes of moderately hypofractionated helical tomotherapy (HT) for the curative treatment of localized prostate cancer (PC). METHODS: From December 2012 to May 2018, 170 patients were treated with definitive intent for PC. Thirty-four percent were low risk, 30% intermediate risk (IR) and 36% high risk (HR). All patients received 70 Gy in 28 fractions to the prostate; 61.6 Gy were delivered to the seminal vesicles for IR; pelvic lymph nodes irradiation for a total dose of 50.4 Gy was added in the HR subgroup. Toxicity was assessed using CTCAE V4.0, and biochemical failure was defined following Phoenix criteria. Time-to-event data were analyzed using the Kaplan-Meier method and log-rank test. RESULTS: The median follow-up was 36 months (range 12-78); acute toxicity was as follows: G1 and G2 in 27.6% and 19.4% for GI; 53% and 24% for GU. No G ≥ 3 event was observed. For late toxicity, G ≥ 3 GI and GU rates were, respectively, 3% and 2.4% at 3 years and 3% and 4.8% at 4 years; no G4 occurred. A statistical correlation between acute or late G3 incidence and clinical or dosimetric parameters was not found. At the time of analysis, 2- and 3-year biochemical relapse-free survival rates were 90% and 87.5% and 2- and 3-year overall survival rates were 96.4% and 90%, respectively. The log-rank test revealed no difference between the risk groups in terms of biochemical control (p = 0.16). CONCLUSIONS: Moderately hypofractionated RT with HT for localized prostate cancer reported excellent outcomes with mild acute and late toxicity incidence, with promising biochemical control rates.
Authors: Ícaro T Carvalho; Willy Baccaglini; Oliver R Claros; Felipe K Chen; Paulo P Kayano; Gustavo C Lemos; Eduardo Weltman; Deborah A Kuban; Arie Carneiro Journal: Acta Oncol Date: 2018-06-08 Impact factor: 4.089
Authors: Anthony L Zietman; Michelle L DeSilvio; Jerry D Slater; Carl J Rossi; Daniel W Miller; Judith A Adams; William U Shipley Journal: JAMA Date: 2005-09-14 Impact factor: 56.272
Authors: Pascal Pommier; Sylvie Chabaud; Jean Leon Lagrange; Pierre Richaud; François Lesaunier; Elisabeth Le Prise; Jean Philippe Wagner; Meng Huor Hay; Veronique Beckendorf; Jean Philippe Suchaud; Pierre Marie Pabot du Chatelard; Valerie Bernier; Nicolas Voirin; David Perol; Christian Carrie Journal: J Clin Oncol Date: 2007-12-01 Impact factor: 44.544
Authors: Patrick A Kupelian; Twyla R Willoughby; Chandana A Reddy; Eric A Klein; Arul Mahadevan Journal: Int J Radiat Oncol Biol Phys Date: 2007-06-04 Impact factor: 7.038
Authors: David P Dearnaley; Gordana Jovic; Isabel Syndikus; Vincent Khoo; Richard A Cowan; John D Graham; Edwin G Aird; David Bottomley; Robert A Huddart; Chakiath C Jose; John H L Matthews; Jeremy L Millar; Claire Murphy; J Martin Russell; Christopher D Scrase; Mahesh K B Parmar; Matthew R Sydes Journal: Lancet Oncol Date: 2014-02-26 Impact factor: 41.316